Snapshot from Jul 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Immutep securities class action lawsuit
Regulatory class action

Immutep securities class action lawsuit

Analysis based on 158 articles · First reported May 18, 2026 · Last updated Jul 06, 2026

Sentiment
-60
Attention
3
Articles
158
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Immutep's stock price collapsed 82% after the trial discontinuation announcement, erasing substantial market value. The class action lawsuits may result in significant financial liability for the company, further pressuring its stock and ability to raise capital.

Biotechnology Pharmaceuticals
Event Summary

Multiple law firms have filed securities class action lawsuits against Immutep Limited (Nasdaq: IMMP) on behalf of investors who purchased shares between March 24, 2025 and March 12, 2026. The lawsuits allege that Immutep made false and misleading statements regarding its TACTI-004 Phase III trial of eftilagimod alfa (efti) for non-small cell lung cancer, concealing that the trial was likely to fail. On March 13, 2026, Immutep announced that an independent data monitoring committee recommended discontinuing the trial for futility, causing its ADR price to drop 82.44% from $2.76 to $0.48. Lead plaintiff deadline is July 6, 2026.

Key Actions
100 Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit Immutep
98 The Schall Law Firm filed class action lawsuit Immutep
95 Levi & Korsinsky filed class action Immutep
92 Rosen Law Firm investigates claims Immutep
90 Robbins LLP filed class action Immutep
89 Immutep issued press release
85 DJS Law Group filed class action lawsuit Immutep
83 Pomerantz LLP filed class action Immutep
60 Jefferies downgraded stock Immutep
60 Baird (investment bank) slashed price target Immutep
60 Mizuho Financial Group downgraded to Market Perform Immutep
60 Maxim Group removed price target Immutep
Entities Involved
stock
Immutep
Immutep is the defendant in multiple securities class action lawsuits alleging fraud related to its TACTI-004 trial. The trial failure and subsequent lawsuits have devastated its stock price and damaged its reputation.
Importance 100.0 Sentiment -90.0
priv
Levi & Korsinsky
Levi & Korsinsky is the law firm representing investors in the securities class action against Immutep. They are actively seeking lead plaintiffs for the lawsuit.
Importance 80.0 Sentiment 70.0
per
Joseph E. Levi
Joseph E. Levi is an attorney at Levi & Korsinsky and is actively involved in the Immutep securities class action, providing guidance and contact information for potential lead plaintiffs.
Importance 70.0 Sentiment 60.0
priv
Rosen Law Firm
Rosen Law Firm is a global investor rights law firm that reminds purchasers of Immutep ADRs of the lead plaintiff deadline for the class action lawsuit.
Importance 68.0 Sentiment 42.0
per
Philip Kim
Philip Kim is associated with Rosen Law Firm, which is reminding investors about the Immutep class action lawsuit.
Importance 40.0 Sentiment 20.0
per
Lawrence Rosen
Lawrence Rosen is a founding partner of Rosen Law Firm, which is leading the securities class action against Immutep.
Importance 40.0 Sentiment 50.0
priv
Baird (investment bank)
Baird (investment bank) is a financial services firm that slashed Immutep's price target and downgraded its stock to Neutral after the trial failure, indicating a loss of confidence in the company's future.
Importance 20.0 Sentiment 0.0
priv
Maxim Group
Maxim Group downgraded Immutep to Hold and removed its price target, citing a significant lack of clarity on the path forward for the company.
Importance 20.0 Sentiment 0.0
priv
Jefferies
Jefferies is an investment bank that downgraded Immutep's stock to Hold following the TACTI-004 trial discontinuation, reflecting the market's negative reaction.
Importance 20.0 Sentiment 0.0
stock
Mizuho Financial Group
Citizens downgraded Immutep to Market Perform, questioning the mechanism of action of efti after the trial's futility analysis.
Importance 20.0 Sentiment 0.0
priv
Robbins LLP
Robbins LLP is one of the law firms representing investors in the class action against Immutep.
Importance 20.0 Sentiment 0.0
priv
Pomerantz LLP
Pomerantz LLP is one of the law firms that filed a class action lawsuit against Immutep, representing investors.
Importance 20.0 Sentiment 0.0
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is one of the law firms that filed a class action lawsuit against Immutep, representing investors.
Importance 20.0 Sentiment 0.0
priv
The Schall Law Firm
The Schall Law Firm is one of the law firms that filed a class action lawsuit against Immutep, representing investors.
Importance 20.0 Sentiment 0.0
priv
DJS Law Group
DJS Law Group is one of the law firms that filed a class action lawsuit against Immutep, representing investors.
Importance 20.0 Sentiment 0.0
+ 9 more entities View on Dashboard
Relationships
Immutep related ↔ Rosen Law Firm
Immutep related ↔ Philip Kim
Immutep related ↔ Lawrence Rosen
Levi & Korsinsky related ↔ Joseph E. Levi
Levi & Korsinsky related ↔ Rosen Law Firm
Levi & Korsinsky related ↔ Philip Kim
Levi & Korsinsky related ↔ Lawrence Rosen
Joseph E. Levi related ↔ Rosen Law Firm
Joseph E. Levi related ↔ Philip Kim
Joseph E. Levi related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Lawrence Rosen
Philip Kim attorney ↔ Lawrence Rosen Philip Kim is an attorney at the Rosen Law Firm, working under the direction of founding partner Lawrence Rosen. Kim fre
Baird (investment bank) related ↔ Jefferies
Jefferies related ↔ Mizuho Financial Group
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.